neuroblastoma
Conditions
Interventions
Conventional Treatment Group:Patient will receive routine visits and health promotion education.
Digital Therapy Group:On the basis of routine treatment in the hospital,online tele-rehabilitation guidance is added and pushed to the patient through the form of a digital prescription for the purpo
Sponsors
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
4 Years to 17 Years
Inclusion criteria
Inclusion criteria: (1)Clinical diagnosis of neuroblastoma and finished postoperative radiotherapy or chemotherapy; (2)4-17 years of age; (3)Patients who can understand and communicate; (4)Patients or legal guardians is able to operate mobile phone applications; (5)Patients or guardians are aware of their illness and prognosis; (6)Patients or guardians volunteer to participate in the study and sign an agreement promising that they will abide by the trial protocol's rules.
Exclusion criteria
Exclusion criteria: (1)Previous malignant tumors, or other types of solid tumors, non-solid tumors; (2)Disease progression (unstable) or recurrence at the time of enrollment; (3)Heart rate exceeding 70% of the maximum allowed heart rate for age, heart rate less than 60 beats/min; blood pressure greater than 110/70mmHg for preschool children (3-6 years old); blood pressure greater than 120/80mmHg for school-age children (6-12 years old); respiratory rate greater than 50 breaths/min; body temperature higher than 37.5°C; blood oxygen saturation less than 90%; (4)Within the 3 months prior to enrollment: heart failure (NYHA functional class II or higher), severe pulmonary function decline, fractures, hypertension levels of =2 degrees and current use of =2 antihypertensive drugs, etc.; (5)Known history of HIV infection, active serological status of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, or any uncontrolled active systemic infection history; (6)Major surgery history within 4 weeks before enrollment, or planned major surgery during the treatment period; (7)Patients currently participating in other clinical studies; (8)The investigator determines that there is any other significant clinical disease or laboratory evidence that affects the participation of the subject in the study; (9)The investigator judges that the subject is unlikely to comply with the study procedures, restrictions, and requirements, and the investigator believes that there are other reasons that make the subject unsuitable for participation in the clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Six-minute walking distance; | — |
Secondary
| Measure | Time frame |
|---|---|
| Body composition;Hand-grip strength;Pediatric Quality of Life Inventory 4.0; | — |
Countries
China
Contacts
Public ContactZhou Xuan
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed